A Targeted Nanozyme for STING Activation Improves BiTEs Therapy Outcomes in Colorectal Cancer

Area of Science:

• Oncology
• Immunotherapy
• Nanomedicine

Background:

• Colorectal cancer (CRC) presents a significant global health challenge due to treatment resistance and high recurrence rates, often linked to immunosuppressive tumor microenvironments.
• Conventional therapies and existing bispecific T-cell engagers (BiTEs) face limitations including poor stability, off-tumor effects, and systemic toxicity, hindering effective cancer immunotherapy.

Purpose of the Study:

• To develop a novel tumor-targeted nanozyme capable of co-delivering immunomodulatory agents and T-cell engaging bispecific antibodies for enhanced colorectal cancer treatment.
• To overcome the limitations of current immunotherapies by creating a stable, tumor-specific delivery system that activates innate immunity and adaptive T-cell responses.

Main Methods:

• A nanozyme (MnO2-dsDNA@BiTE/APT) was engineered, utilizing manganese dioxide (MnO2) to carry double-strand DNA (dsDNA), a STING agonist, and surface-loading with a PD-L1/CD3 bispecific T-cell engager (BiTE).
• The nanozyme was functionalized with an aptamer (APT) for active tumor targeting, enabling localized release of dsDNA, Mn2+, and BiTE upon reaching the tumor site.
• The study investigated the synergistic effects of dsDNA-mediated STING pathway activation and BiTE-induced T-cell cytotoxicity in remodeling the tumor microenvironment.

Main Results:

• The developed nanozyme demonstrated effective tumor accumulation and localized release of its therapeutic payloads (dsDNA, Mn2+, BiTE).
• Co-delivery synergistically activated the STING pathway, successfully remodeling the immunosuppressive tumor microenvironment.
• Enhanced T-cell-mediated cytotoxicity was observed, indicating potentiation of the anti-tumor immune response.

Conclusions:

• The tumor-targeted nanozyme represents a promising strategy for enhancing colorectal cancer immunotherapy by integrating innate immune stimulation with adaptive T-cell engagement.
• This approach offers a potential solution to overcome the challenges of immunosuppression and recurrence in colorectal cancer treatment.